Profound Medical Corp T.PRN

Alternate Symbol(s): PROF

Healthcare Medical Devices

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

TSX:PRN - Post by User

Profound Medical Corp

Bullboard Posts

Comment by ebrie014on May 10, 2018 8:57pm

128 Views

Post# 28015659

RE:quarterly results

Some highlights from CC:

Exploring a recurring revenue only model with sales force for Tulsa to ramp up quicker and avoid from paying a large upfront cost but have a higher recurring revenue stream
Second half sales to be higher due to China launch of Sonnalleve
2/3 patients in trial are intermediate patients which have lower risk of side effects and will prove out that it can be an effective product for earlier stage and later stage.
Both Tulsa and Sonnalleve are in Phillips and Siemen's catalogue as of Q2-18 which should also help ramp up in second half 2018.
In talks with FDA for Sonnelleve approval in US
Looking at improved manufacturing facilties for Sonnalleve production
May 21st interim data and next news release should show full interim results of trial (I personally expect this to be a catalyst)